PRLR and ovarian carcinoma: More recently, prolonged treatment with hPRL-G129R in ovarian cancer models was found to antagonize the signaling activities of the prolactin/PRLR tumoral axis and to inhibit tumor growth by inducing destructive autophagy [25].